Alector, Inc. (ALEC)
Market Cap | 214.47M |
Revenue (ttm) | 61.51M |
Net Income (ttm) | -158.41M |
Shares Out | 97.93M |
EPS (ttm) | -1.70 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,433,990 |
Open | 2.350 |
Previous Close | 2.520 |
Day's Range | 2.140 - 2.415 |
52-Week Range | 2.140 - 8.900 |
Beta | 0.51 |
Analysts | Strong Buy |
Price Target | 14.00 (+539.27%) |
Earnings Date | Nov 6, 2024 |
About ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The compa... [Read more]
Financial Performance
In 2023, Alector's revenue was $97.06 million, a decrease of -27.36% compared to the previous year's $133.62 million. Losses were -$130.39 million, -2.19% less than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ALEC stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 539.27% from the latest price.
News
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program.
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has en...
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will pa...
Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenth...
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024
Alector to Host Mid-Year Earnings Conference Call
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baselin...
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related t...
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain bar...
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally The trial, being conducted in partnership with GSK, is expected to enroll approximately 28...
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
-Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthrough Therapy Designation for the...
Alector Announces Closing of Public Offering
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its unde...
Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation
Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using ...
Alector Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an under...
Alector Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it intends to offe...
Alector: Good Data, Huge Cash, No Near Term Catalyst
Alector's stock has traded mostly sideways, down 18% from last year, despite having a promising late-stage CNS pipeline, loads of cash, and two big partnerships. The company has trimmed down its pipel...
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively Leading scientific and clinical experts to p...
Alector to Participate in the Stifel Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will partici...
Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants